This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
With a rising number of COVID-19 cases due to the omicron variant, the FDA is making big moves. First, Pfizer's COVID-19 booster has been authorized for those ages 12 to 15. The agency also reduced the amount of time to wait between receiving a second vaccine dose and booster from six months to five. Finally, a third primary series dose of Pfizer's shot is approved for immunocompromised children five to 11 years old. Professor Peter Pitts joins Cheddar News to discuss.
California's new composting law will affect what residents do in their kitchens. As of this week, Californians will have to recycle excess food in an effort to reduce emissions caused by food waste. Cities and counties will turn recycled food into compost or use it as a renewable energy source. California's new law is the largest mandatory residential food waste recycling program in the country. Rachel Wagoner, Director of the California Department of Resources, Recycling and Recovery called the law 'the biggest change to trash' since recycling started in the 1980s. She joined Cheddar Climate to discuss.
Deborah Brosnan, President of Deborah Brosnan & Associates, joins Cheddar Climate, where she explains why global warming brought about 'a year of reckoning' in 2021 and why previously unprecedented weather events could become the norm going forward.
On this episode of Cheddar Reveals, Dr. Anita Gupta, Adjunct assistant professor of anesthesiology and critical care medicine at the Johns Hopkins University School of Medicine, shares her forecast for the healthcare industry in 2022; Waseem Asghar, Ph.D., Associate Professor, Department of Computer & Electrical Engineering and Computer Science, Florida Atlantic University, breaks down the latest progress, trends, and innovations in wearable health tech; Cheddar gets a look at Curiosity Stream's 'Hacking our Biome.'
Dr. Anita Gupta, Adjunct assistant professor of anesthesiology and critical care medicine at the Johns Hopkins University School of Medicine, joins Cheddar Reveals to share her forecast for the healthcare industry in 2022.
Waseem Asghar, Ph.D., Associate Professor, Department of Computer & Electrical Engineering and Computer Science, Florida Atlantic University, joins Cheddar Reveals to break down the latest progress, trends, and innovations in wearable health tech.
Washington DC and the surrounding areas saw a record breaking snow storm Monday as a strong storm system works its way across the eastern U.S. The extreme weather event caused extensive damage in the greater Washington area, leaving thousands in the region without power. Jonathan Porter, Chief Meteorologist, AccuWeather, joined Wake Up with Cheddar to discuss the fierce storm.
Sweta Chakraborty, U.S. President of We Don't Have Time and climate change expert, joins Cheddar News to discuss how mining the proper resources for the clean energy sector is crucial.
Over the past year alone, we've seen an increasing push-back on fossil fuels, legislation to reduce plastic pollution, greater protection over our worlds' forests, and a growing number of companies working to reduce total carbon footprint. To discuss the sustainability trends that defined 2021 and the changes individuals can make in 2022, J.D. Durkin is joined by Ashlee Piper, a sustainability expert and author of 'Give a Sh*t: Do Good. Live Better. Save the Planet,' joins Cheddar News.
